Fairbanks Pharmaceuticals, Inc

Fairbanks Pharmaceuticals is developing novel treatments for diabetes that address the underlying cause of the disease and not just the symptoms. Our goal is to facilitate repair of existing insulin-producing beta cells in the short term and regeneration of new beta cells in the longer term. In June 2018 Fairbanks received a Phase II SBIR grant to fund prototype development and testing in mice while in October we were awarded the 2018 Boston Innovation Prize by Boehringer Ingelheim which included a golden ticket to LabCentral.